Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx.

e14589 Background: Developing clinically relevant and highly reproducible scoring methods for PD-L1 to identify patients who will respond effectively to anti-PD-1 therapy is key in the development of companion or complementary diagnostic assays. Methods: Scoring method for PD-L1 IHC 22C3 pharmDx in NSCLC have only captured the percentage on stained tumor cells using the tumor proportion score (TPS) (Roach et al. 2016, Appl Immunohistochem Mol...